1.Alternative Name：Delta3
2.Target：DLL3
3.Source：Human DLL3 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence：Ala27-Leu492
5.Protein structure:Q9NYJ7hFC
6.Molecular Characterization:The protein has a calculated MW of 74kDa.The reducing (R) heterodimer protein migrates as 70-90 kDa due to glycosylation
7.Purity:SDS-PAGE>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.

11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.ELISA

When Recombinant Human DLL3 / hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human DLL3(Rovalpituzumab) that produces 50% of the optimal binding response is approximately 60 ng/ml.

13.Note：For research use only .